GlaxoSmithKline Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on Jun 30, 2026
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals reported FY2026 consolidated revenue from operations of Rs. 3,82,167 Lakhs, up 1.9% from Rs. 3,74,921 Lakhs in FY2025. Profit after tax grew 11.7% to Rs. 1,03,598 Lakhs from Rs. 92,758 Lakhs. EPS increased to Rs. 61.15 from Rs. 54.76. The Board recommended a final dividend of Rs. 57 per share (face value Rs. 10), up from Rs. 54 per share last year, subject to shareholder approval at the 101st AGM on June 30, 2026. The record date for dividend entitlement is May 29, 2026. Statutory auditors Deloitte Haskins & Sells LLP issued an unmodified (clean) opinion on both standalone and consolidated financial statements. Exceptional items included credit of Rs. 2,062 Lakhs from sale of surplus properties.
The company demonstrated steady earnings growth with PAT up 11.7% despite modest 1.9% revenue growth, indicating margin improvement. Higher dividend payout signals management confidence. Clean audit opinion with no going concern issues is positive for investor confidence.